Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B7
Source: 0001140361-25-000631
Chunk: 8

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B7
Chunk 8
---
 Merger, Old Cartesian (as the First Step Surviving Corporation) merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving company, or the Surviving Company, and continued under the name “Cartesian Bio, LLC”, or the Second Merger and, together with the First Merger, the Merger. In connection with the Merger and pursuant to the Merger Agreement, the Company (which was known as Selecta Biosciences, Inc. until immediately prior to the Merger) changed its corporate name to Cartesian Therapeutics, Inc.

Our principal executive offices are located at 7495 New Horizon Way, Frederick, MD 21703, and our telephone number is (301) 348-8698.

<div align='center'>6</div>

TABLE OF CONTENTS

THE OFFERING Shares Offered by the Selling Stockholders Up to (i) 5,813,223 shares of Common Stock and (ii) 437,927 shares of Common Stock issuable upon the conversion of 437,927 shares of Series B Preferred Stock. Terms of the Offering The Selling Stockholders will determine when and how they will dispose of the shares of Common Stock and shares of Common Stock issuable upon conversion of Series B Preferred Stock registered under this prospectus for resale. Shares Outstanding As of September 30, 2024, there were 23,896,525 shares of our Common Stock, 166,341.592 shares of Series A Preferred Stock and 437,927 shares of Series B Preferred Stock outstanding. Use of Proceeds We will not receive any proceeds from the sale of the Resale Shares offered by the Selling Stockholders under this prospectus. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. See the section titled “ Use of Proceeds.” Risk Factors See the section titled “ Risk Factors” and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our securities. Trading Markets and Ticker Symbols Our Common Stock is listed on the Nasdaq Global Market under the symbol “RNAC.” The number of shares of our Common Stock outstanding is based on 23,896,525 shares of our Common Stock outstanding as of September 30, 2024. The number of shares outstanding as of September 30, 2024 excludes as of such date:

| • | 5,544,719 shares of Common Stock issuable upon